Published in J Infect Dis on December 09, 2003
Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2006) 8.90
Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol (2010) 6.18
Molecular epidemiology of tuberculosis: current insights. Clin Microbiol Rev (2006) 3.79
Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog (2006) 2.26
Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis (2009) 2.25
Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS6110 clustering rather than ethambutol resistance. Antimicrob Agents Chemother (2005) 2.17
The infectiousness of tuberculosis patients coinfected with HIV. PLoS Med (2008) 2.08
Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci U S A (2006) 2.00
Transmission of Multidrug-Resistant and Drug-Susceptible Tuberculosis within Households: A Prospective Cohort Study. PLoS Med (2015) 1.86
Type 2 diabetes and multidrug-resistant tuberculosis. Scand J Infect Dis (2008) 1.40
Beijing sublineages of Mycobacterium tuberculosis differ in pathogenicity in the guinea pig. Clin Vaccine Immunol (2012) 1.24
Are sputum samples of retreatment tuberculosis reaching the reference laboratories? A 9-year audit in Tanzania. Public Health Action (2013) 1.23
Differences among sublineages of the East-Asian lineage of Mycobacterium tuberculosis in genotypic clustering. Int J Tuberc Lung Dis (2010) 1.13
Determinants of cluster size in large, population-based molecular epidemiology study of tuberculosis, northern Malawi. Emerg Infect Dis (2008) 1.01
Minimal diversity of drug-resistant Mycobacterium tuberculosis strains, South Africa. Emerg Infect Dis (2014) 0.97
Drug resistance and fitness in Mycobacterium tuberculosis infection. J Infect Dis (2005) 0.93
Determinants of multidrug-resistant tuberculosis clusters, California, USA, 2004-2007. Emerg Infect Dis (2010) 0.91
Reduced virulence of an extensively drug-resistant outbreak strain of Mycobacterium tuberculosis in a murine model. PLoS One (2014) 0.84
The use of anti-tuberculosis therapy for latent TB infection. Infect Drug Resist (2010) 0.84
Methodological and Clinical Aspects of the Molecular Epidemiology of Mycobacterium tuberculosis and Other Mycobacteria. Clin Microbiol Rev (2016) 0.84
Heightened vulnerability to MDR-TB epidemics after controlling drug-susceptible TB. PLoS One (2010) 0.79
Transmission of isoniazid-resistant tuberculosis. J Infect Dis (2004) 0.78
Chest Radiographic Patterns and the Transmission of Tuberculosis: Implications for Automated Systems. PLoS One (2016) 0.77
Fitness Costs of Drug Resistance Mutations in Multidrug-Resistant Mycobacterium tuberculosis: A Household-Based Case-Control Study. J Infect Dis (2015) 0.77
Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. PLoS One (2012) 0.76
Long term follow-up of drug resistant and drug susceptible tuberculosis contacts in a Low incidence setting. BMC Infect Dis (2012) 0.75
Virulence of Mycobacterium tuberculosis after Acquisition of Isoniazid Resistance: Individual Nature of katG Mutants and the Possible Role of AhpC. PLoS One (2016) 0.75
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med (2003) 14.40
Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis (2006) 9.35
Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2006) 8.90
Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis (2007) 6.45
Clinical practice. Latent tuberculosis infection. N Engl J Med (2002) 5.64
Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med (2002) 5.42
The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science (2006) 5.41
Stable association between strains of Mycobacterium tuberculosis and their human host populations. Proc Natl Acad Sci U S A (2004) 4.98
Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet (2010) 4.94
Functional and evolutionary genomics of Mycobacterium tuberculosis: insights from genomic deletions in 100 strains. Proc Natl Acad Sci U S A (2004) 4.78
High functional diversity in Mycobacterium tuberculosis driven by genetic drift and human demography. PLoS Biol (2008) 4.74
Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis (2006) 4.63
Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med (2002) 4.14
Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis (2008) 4.14
Genomic deletions classify the Beijing/W strains as a distinct genetic lineage of Mycobacterium tuberculosis. J Clin Microbiol (2005) 3.67
Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis (2011) 3.62
Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med (2007) 3.32
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med (2006) 3.20
Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med (2010) 3.18
Progression to active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis lineage in The Gambia. J Infect Dis (2008) 3.15
Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J (2012) 3.00
Tuberculosis diagnosis--time for a game change. N Engl J Med (2010) 2.96
Does DOTS work in populations with drug-resistant tuberculosis? Lancet (2005) 2.95
Tuberculosis and diabetes in southern Mexico. Diabetes Care (2004) 2.83
Diagnostic accuracy of same-day microscopy versus standard microscopy for pulmonary tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis (2012) 2.80
The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J (2013) 2.80
Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med (2004) 2.75
Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review. PLoS Med (2007) 2.71
Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis (2010) 2.61
Interferon-γ release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis (2011) 2.59
The W-Beijing lineage of Mycobacterium tuberculosis overproduces triglycerides and has the DosR dormancy regulon constitutively upregulated. J Bacteriol (2007) 2.42
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis (2009) 2.36
Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis. Clin Infect Dis (2007) 2.33
Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med (2014) 2.29
Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog (2006) 2.26
Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis (2009) 2.25
Yield of sputum induction in the diagnosis of pleural tuberculosis. Am J Respir Crit Care Med (2003) 2.15
Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis. PLoS Med (2011) 2.14
Linezolid for multidrug-resistant tuberculosis. Lancet Infect Dis (2012) 2.00
Integrated strategies to optimize sputum smear microscopy: a prospective observational study. Am J Respir Crit Care Med (2010) 1.95
Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr (2011) 1.95
The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med (2012) 1.94
Advances in the diagnosis and treatment of tuberculosis. Proc Am Thorac Soc (2006) 1.94
Sensitivity of direct versus concentrated sputum smear microscopy in HIV-infected patients suspected of having pulmonary tuberculosis. BMC Infect Dis (2009) 1.92
Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis. Clin Vaccine Immunol (2008) 1.80
The in vitro evolution of BCG vaccines. Vaccine (2003) 1.80
Reaching the limits of tuberculosis prevention among foreign-born individuals: a tuberculosis-control program perspective. Clin Infect Dis (2008) 1.74
Large sequence polymorphisms classify Mycobacterium tuberculosis strains with ancestral spoligotyping patterns. J Clin Microbiol (2007) 1.68
Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med (2015) 1.68
Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis (2005) 1.63
Mycobacterium africanum elicits an attenuated T cell response to early secreted antigenic target, 6 kDa, in patients with tuberculosis and their household contacts. J Infect Dis (2006) 1.56
Hypersensitivity pneumonitis reaction to Mycobacterium avium in household water. Chest (2005) 1.49
Pulmonary specialty training to improve respiratory health in low- and middle-income countries. Needs and challenges. Ann Am Thorac Soc (2015) 1.47
Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial. Clin Infect Dis (2004) 1.46
Global scale-up of the programmatic management of multidrug-resistant tuberculosis. Indian J Tuberc (2014) 1.43
Use of spoligotyping and large sequence polymorphisms to study the population structure of the Mycobacterium tuberculosis complex in a cohort study of consecutive smear-positive tuberculosis cases in The Gambia. J Clin Microbiol (2009) 1.41
Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med (2012) 1.41
Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother (2005) 1.40
Profiling antibodies to Mycobacterium tuberculosis by multiplex microbead suspension arrays for serodiagnosis of tuberculosis. Clin Vaccine Immunol (2007) 1.38
Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis. BMC Infect Dis (2011) 1.38
Genomic interrogation of ancestral Mycobacterium tuberculosis from south India. Infect Genet Evol (2007) 1.37
Transmission of drug-resistant tuberculosis among treated patients in Shanghai, China. J Infect Dis (2007) 1.36
Gene expression diversity among Mycobacterium tuberculosis clinical isolates. Microbiology (2005) 1.36
A systematic review of commercial serological antibody detection tests for the diagnosis of extrapulmonary tuberculosis. Thorax (2007) 1.35
Notes from the Field: Mycobacterium chimaera Contamination of Heater-Cooler Devices Used in Cardiac Surgery - United States. MMWR Morb Mortal Wkly Rep (2016) 1.27
Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med (2006) 1.24
Beijing sublineages of Mycobacterium tuberculosis differ in pathogenicity in the guinea pig. Clin Vaccine Immunol (2012) 1.24
Evaluating tuberculosis case detection via real-time monitoring of tuberculosis diagnostic services. Am J Respir Crit Care Med (2011) 1.24
Mycobacterium tuberculosis Beijing strains favor transmission but not drug resistance in China. Clin Infect Dis (2012) 1.22
High-throughput method for detecting genomic-deletion polymorphisms. J Clin Microbiol (2004) 1.21
Use of whole genome sequencing to determine the microevolution of Mycobacterium tuberculosis during an outbreak. PLoS One (2013) 1.19
Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. Am J Respir Crit Care Med (2010) 1.18
International Standards for Tuberculosis Care: revisiting the cornerstones of tuberculosis care and control. Expert Rev Anti Infect Ther (2007) 1.18
Association between embB codon 306 mutations and drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2007) 1.17
A molecular epidemiological assessment of extrapulmonary tuberculosis in San Francisco. Clin Infect Dis (2003) 1.15
Diagnosis and treatment of infections due to Mycobacterium avium complex. Semin Respir Crit Care Med (2008) 1.15
Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis. PLoS One (2010) 1.15
Rapid identification and susceptibility testing of Mycobacterium tuberculosis from MGIT cultures with luciferase reporter mycobacteriophages. J Med Microbiol (2003) 1.13
Mycobacterium africanum: a new opportunistic pathogen in HIV infection? AIDS (2005) 1.13
IL-9 is associated with an impaired Th1 immune response in patients with tuberculosis. Clin Immunol (2007) 1.13
Does resistance to pyrazinamide accurately indicate the presence of Mycobacterium bovis? J Clin Microbiol (2005) 1.11
Evaluation of quantitative IFN-gamma response for risk stratification of active tuberculosis suspects. Am J Respir Crit Care Med (2009) 1.09
Clinical management of tuberculosis in the context of HIV infection. Annu Rev Med (2004) 1.09
Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China. Antimicrob Agents Chemother (2009) 1.09
Selection of mutations to detect multidrug-resistant Mycobacterium tuberculosis strains in Shanghai, China. Antimicrob Agents Chemother (2009) 1.08